THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study (Q26780084)

1

Giovanni Corona

0 references

Mario Maggi

9

Mario Maggi

0 references

Linda Vignozzi

4

Linda Vignozzi

0 references

Edoardo Mannucci

8

Edoardo Mannucci

0 references

Vito Angelo Giagulli

2

Vito A Giagulli

0 references

Elisa Maseroli

3

Elisa Maseroli

0 references

Farid Saad

7

Farid Saad

0 references

author name string

Michael Zitzmann

European Journal of Endocrinology

6

0 references

language of work or name

English

0 references

publication date

March 2016

0 references

published in

0 references

volume

174

0 references

page(s)

R99-116

0 references

issue

3

0 references

cites work

Testosterone therapy in glucocorticoid-treated men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Long-term drug treatment for obesity: a systematic and clinical review

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Psychological interventions for overweight or obesity

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Androgen treatment of abdominally obese men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone substitution increases the activity of lipoprotein lipase and hepatic lipase in hypogonadal males

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

The effect of testosterone on insulin sensitivity in men with heart failure.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

https://api.crossref.org/works/10.1530%2FEJE-15-0262

1 reference

7 January 2021

Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Muscular strength, body composition and health responses to the use of testosterone enanthate: a double blind study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

How to recognize late-onset hypogonadism in men with sexual dysfunction

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

DHEA in elderly women and DHEA or testosterone in elderly men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Gonadal steroids and body composition, strength, and sexual function in men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Impact of testosterone treatment on postprandial triglyceride metabolism in elderly men with subnormal testosterone levels

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomised controlled study.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Increase in hepatic lipase activity after testosterone substitution in men with hypogonadism of pituitary origin

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of oral testosterone undecanoate on growth, body composition, strength and energy expenditure of adolescent boys

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Randomized clinical trial of testosterone replacement therapy in hypogonadal men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Type 2 diabetes mellitus and testosterone: a meta-analysis study.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Prevalence of late-onset hypogonadism in men with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

The impact of extended care on the long-term maintenance of weight loss: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Is obesity a further cardiovascular risk factor in patients with erectile dysfunction?

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone and metabolic syndrome: a meta-analysis study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Endogenous testosterone level and testosterone supplementation therapy in chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Bariatric surgery: a best practice article

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone dose-response relationships in healthy young men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Strength training and testosterone treatment have opposing effects on migration inhibitor factor levels in ageing men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Androgen Receptor Gene CAG Repeat Polymorphism Regulates the Metabolic Effects of Testosterone Replacement Therapy in Male Postsurgical Hypogonadotropic Hypogonadism

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Abdominal adiposity distribution in diabetic/prediabetic and nondiabetic populations: a meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Differential anabolic effects of testosterone and amino acid feeding in older men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

The short-term effects of high-dose testosterone on sleep, breathing, and function in older men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Do the effects of testosterone on muscle strength, physical function, body composition, and quality of life persist six months after treatment in intermediate-frail and frail elderly men?

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

A randomized pilot study of monthly cycled testosterone replacement or continuous testosterone replacement versus placebo in older men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS).

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Pharmacokinetics, bioefficacy, and safety of sublingual testosterone cyclodextrin in hypogonadal men: comparison to testosterone enanthate--a clinical research center study.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of modest testosterone supplementation and exercise for 12 weeks on body composition and quality of life in elderly men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone therapy decreases subcutaneous fat and adiponectin in aging men

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Short term testosterone replacement therapy improves libido and body composition

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effects of testosterone treatment on body composition in males with testosterone deficiency syndrome

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effect of testosterone replacement therapy on bone mineral density in patients with Klinefelter syndrome

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone and Cardiovascular Risk in Men: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Erectile dysfunction and central obesity: an Italian perspective

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism.

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Meta-analysis: pharmacologic treatment of obesity

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1530%2FEJE-15-0262

7 January 2021

Identifiers

DOI

10.1530/EJE-15-0262

1 reference

Consolidated OpenCitations Corpus – April 2017

3093926

3093926

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference